{"id":"https://openalex.org/W4393085508","doi":"https://doi.org/10.1158/1538-7445.am2024-5925","title":"Abstract 5925: Safety, efficacy, pharmacokinetics, and pharmacodynamics of a second generation Irofulven analog CAP-0121 in preclinical cancer models","display_name":"Abstract 5925: Safety, efficacy, pharmacokinetics, and pharmacodynamics of a second generation Irofulven analog CAP-0121 in preclinical cancer models","publication_year":2024,"publication_date":"2024-03-22","ids":{"openalex":"https://openalex.org/W4393085508","doi":"https://doi.org/10.1158/1538-7445.am2024-5925"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-5925","doi":"https://doi.org/10.1158/1538-7445.am2024-5925","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-5925","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063894679","display_name":"Raymond T. Suhandynata","orcid":"https://orcid.org/0000-0002-4767-7639","observed_orcids":["https://orcid.org/0000-0002-4767-7639"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raymond T. Suhandynata","raw_affiliation_strings":["1UC San Diego, La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UC San Diego, La Jolla, CA;","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102634049","display_name":"Tk Nguyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T K. Nguyen","raw_affiliation_strings":["1UC San Diego, La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UC San Diego, La Jolla, CA;","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088164052","display_name":"Venkata Ramana Kotamraju","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Venkata R. Kotamraju","raw_affiliation_strings":["2Califia Pharma, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Califia Pharma, San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064787976","display_name":"Jeremiah D. Momper","orcid":"https://orcid.org/0000-0002-3154-6685","observed_orcids":["https://orcid.org/0000-0002-3154-6685","https://orcid.org/0009-0009-8285-5611"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremiah D. Momper","raw_affiliation_strings":["1UC San Diego, La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UC San Diego, La Jolla, CA;","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111493412","display_name":"Michael J. Kelner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Kelner","raw_affiliation_strings":["1UC San Diego, La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1UC San Diego, La Jolla, CA;","institution_ids":["https://openalex.org/I36258959"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"6_Supplement","first_page":"5925","last_page":"5925"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.49729999899864197,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.49729999899864197,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11547","display_name":"Sesquiterpenes and Asteraceae Studies","score":0.16699999570846558,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.0575999990105629,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/irofulven","display_name":"irofulven","score":0.9459999799728394},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.824999988079071},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9850000143051147},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8669999837875366},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.5529999732971191},{"id":"https://openalex.org/keywords/neutrophil-count","display_name":"neutrophil count","score":0.7540000081062317},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.5759999752044678},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.7879999876022339},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6209999918937683},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.42500001192092896},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.5220000147819519},{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.43799999356269836}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7555575370788574},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7257572412490845},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5646147727966309},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5305412411689758},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5136250853538513},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.4794151484966278},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.14218628406524658},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.09179985523223877}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-5925","doi":"https://doi.org/10.1158/1538-7445.am2024-5925","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-5925","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8100000023841858}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2254638634","https://openalex.org/W2369345461","https://openalex.org/W2594910449","https://openalex.org/W4364376666","https://openalex.org/W2960553615","https://openalex.org/W3043458966","https://openalex.org/W2162491061","https://openalex.org/W1969203961","https://openalex.org/W2227061539","https://openalex.org/W2307066354"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Irofulven":[2,451],"is":[3,398,423],"a":[4,34,164,172,225,335,392,448],"semisynthetic":[5],"sesquiterpene":[6],"anticancer":[7,373,408],"agent":[8],"initially":[9],"investigated":[10],"for":[11,68,101,291,299,333,346,400,412,465],"its":[12,43],"unique":[13],"mechanism":[14],"of":[15,33,129,238,253,260,359,384,410,447,461],"action":[16],"and":[17,31,42,45,72,76,80,132,138,186,190,193,202,216,222,241,256,340,445],"potential":[18,407],"to":[19,52,146,208,264,271,279,312,319,370,403],"overcome":[20],"resistance":[21],"observed":[22,123,345],"in":[23,47,66,199,268,323,337,352,371,396,420,454],"other":[24],"chemotherapeutics.":[25],"This":[26],"study":[27,358],"investigates":[28],"the":[29,116,148,281,304,376,382,406,462],"pharmacokinetics":[30],"pharmacodynamics":[32,446],"second":[35,449],"generation":[36,450],"irofulven":[37,69,182,221,272,302,313],"analog,":[38],"CAP-121":[39,77,187,223,261,276,300,309,347,360,363,385,401,411],"(Califia":[40],"Pharma),":[41],"efficacy":[44],"safety":[46],"preclinical":[48,455],"cancer":[49,169,177,456],"models":[50,161,380,457],"relative":[51,207],"irofulven.":[53,387],"Methods:":[54],"24-hour":[55],"comprehensive":[56],"PK":[57,97,111,366],"was":[58,156,262,277,288,310,330,343],"performed":[59],"at":[60,224,236,251,303,348],"two":[61,377],"different":[62],"intravenous":[63],"(IV)":[64],"doses":[65,237,252],"canines":[67,269],"(0.2":[70],"mg/kg":[71,79,227,240,255,351],"1":[73,226,242,254,472],"mg/kg;":[74,184],"MTD)":[75,185],"(1":[78,307],"3":[81,257],"mg/kg).":[82,308],"Plasma":[83],"concentrations":[84],"were":[85,99,141,179,205,218,296],"measured":[86,142],"by":[87],"ultra-high":[88],"performance":[89],"liquid":[90],"chromatography":[91],"multiple":[92],"reaction":[93],"monitoring":[94],"mass":[95],"spectrometry.":[96],"parameters":[98,112],"determined":[100],"both":[102],"compounds":[103],"using":[104],"noncompartmental":[105],"methods":[106],"(Phoenix":[107],"WinNonlin,":[108],"version":[109],"8.4).":[110],"included":[113],"area":[114],"under":[115],"concentration":[117,124],"vs":[118,301],"time":[119],"curve":[120],"(AUC),":[121],"maximum":[122,149],"(Cmax),":[125],"clearance":[126],"(CL),":[127],"volume":[128],"distribution":[130],"(Vd),":[131],"elimination":[133],"half-life":[134],"(t1/2).":[135],"Canine":[136,293],"platelet":[137,153,203,282,286,341],"neutrophil":[139],"counts":[140,204],"across":[143],"28":[144],"days":[145],"ascertain":[147],"tolerated":[150],"dose":[151,306],"(MTD);":[152],"count":[154],"reversibility":[155],"also":[157],"assessed.":[158],"Mice":[159],"xenograft":[160,325,379],"implanted":[162],"with":[163,181,284,317],"drug":[165],"resistant":[166],"human":[167,174],"ovarian":[168],"(A2870),":[170],"or":[171],"drug-resistant":[173,378],"metastatic":[175],"lung":[176],"(MV522),":[178],"dosed":[180],"(9":[183],"(15,":[188],"20,":[189],"25":[191,350],"mg/kg)":[192],"resulting":[194],"tumor":[195,321],"mass,":[196],"%":[197],"change":[198,336],"body":[200,338],"weight,":[201],"compared":[206,270,402],"vehicle":[209],"only.":[210],"Results:":[211],"Systemic":[212],"exposure,":[213],"CL,":[214],"Vd,":[215],"t1/2":[217],"similar":[219],"between":[220],"IV":[228],"dose.":[229],"For":[230,244],"irofulven,":[231,404],"exposure":[232,246],"increased":[233,247],"approximately":[234],"proportionally":[235,250],"0.2":[239],"mg/kg.":[243,258],"CAP-121,":[245],"less":[248],"than":[249],"MTD":[259,329],"found":[263],"be":[265],"3-fold":[266,274,297],"higher":[267,298],"as":[273],"more":[275],"required":[278],"match":[280],"reduction":[283],"irofulven;":[285],"nadir":[287,294],"rapidly":[289],"reversible":[290],"CAP-121.":[292],"platelets":[295],"same":[305],"superior":[311],"(p":[314],"<":[315],"0.02)":[316],"regards":[318,369],"final":[320],"weights":[322],"mice":[324],"models,":[326],"even":[327],"though":[328],"not":[331,344],"reached":[332],"CAP-121;":[334],"weight":[339],"loss":[342],"up":[349],"mice.":[353],"Conclusion:":[354],"The":[355],"canine":[356],"PK/PD":[357],"demonstrates":[361],"that":[362],"has":[364],"favorable":[365],"parameters.":[367],"With":[368],"vivo":[372],"cytotoxic":[374],"activity,":[375],"confirm":[381],"superiority":[383],"over":[386],"Together,":[388],"these":[389],"findings":[390],"indicate":[391],"wider":[393],"therapeutic":[394],"window":[395],"humans":[397],"expected":[399],"emphasizing":[405],"utility":[409],"solid":[413],"cancers":[414],"without":[415],"prolonged":[416],"thrombocytopenia.":[417],"Further":[418],"investigation":[419],"clinical":[421],"trials":[422],"warranted":[424],"Citation":[425],"Format:":[426],"Raymond":[427],"T.":[428],"Suhandynata,":[429],"T":[430],"K.":[431],"Nguyen,":[432],"Venkata":[433],"R.":[434],"Kotamraju,":[435],"Jeremiah":[436],"D.":[437],"Momper,":[438],"Michael":[439],"J.":[440],"Kelner.":[441],"Safety,":[442],"efficacy,":[443],"pharmacokinetics,":[444],"analog":[452],"CAP-0121":[453],"[abstract].":[458],"In:":[459],"Proceedings":[460],"American":[463],"Association":[464],"Cancer":[466,484],"Research":[467],"Annual":[468],"Meeting":[469],"2024;":[470],"Part":[471],"(Regular":[473],"Abstracts);":[474],"2024":[475],"Apr":[476],"5-10;":[477],"San":[478],"Diego,":[479],"CA.":[480],"Philadelphia":[481],"(PA):":[482],"AACR;":[483],"Res":[485],"2024;84(6_Suppl):Abstract":[486],"nr":[487],"5925.":[488]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2025-10-10T00:00:00"}